Contract Biomanufacturing Services Market

The global contract biomanufacturing services market reached USD 18.3 billion in 2025 and is estimated at USD 20.3 billion in 2026. Revenue is forecast at USD 46.7 billion by 2034, equivalent to an 11.0% CAGR for 2026–2034.

Contract biomanufacturing encompasses third-party manufacture of biological drug substance, sterile drug product, and directly related GMP process and analytical services. The commercial unit is a fee earned by a contract manufacturer for work supplied to an independent sponsor. Sales of the final therapeutic product, the sponsor’s internal manufacturing costs, stand-alone equipment purchases, and discovery-only research services are excluded. This separation prevents the same batch from being counted once as a contractor invoice and again as the market value of the finished medicine.

Lonza reported CHF 6.5 billion in 2025 continuing CDMO sales, including non-biological chemistry and specialized modalities. Samsung Biologics reported KRW 4,557 billion of 2025 revenue for its post-separation CDMO business. These company figures demonstrate the financial scale of outsourced production but are not directly additive to a biologics-only market because each supplier uses a different reporting perimeter. Cross-company comparisons must remove small-molecule services, unrelated analytical work, intercompany transfers and nonmanufacturing contracts.

FUJIFILM Biotechnologies opened its Holly Springs, North Carolina facility in September 2025 with eight 20,000-liter mammalian bioreactors in the initial phase. The company also signed a ten-year U.S. manufacturing agreement with Regeneron worth more than USD 3 billion across the contract term. This investment and commercial commitment illustrate how large sponsors reserve validated production capacity rather than necessarily owning every manufacturing asset. The agreement value is not annual revenue and should be recognized only as services are performed.

Thermo Fisher completed the acquisition of Sanofi’s Ridgefield, New Jersey sterile fill-finish facility in September 2025, retaining Sanofi as a manufacturing customer. FDA guidance calls for quality agreements specifying the responsibilities of product owners and contractors. EMA GMP requirements also apply to imported medicines supplied to the European Union. Accordingly, plant qualification, process comparability, batch-release documentation and inspection history influence outsourcing decisions alongside capacity, cost and delivery schedules.

Source: Lonza 2025; Samsung Biologics 2025; FUJIFILM Holly Springs; FDA quality agreements.

Revenue represents fees paid by independent sponsors to providers for contracted biological manufacturing, GMP testing linked to manufacturing and process transfer. Product sales and the sponsor’s own factory expenses are excluded.

Biologics sponsors seek validated capacity without owning every facility

FUJIFILM Biotechnologies opened the first phase of its Holly Springs plant in September 2025 with eight 20,000-liter mammalian bioreactors. The company also secured a ten-year production arrangement with Regeneron valued above USD 3 billion across its life. Long-duration reservations allow sponsors to avoid constructing their own plants while supporting capital investment by manufacturers. Actual market revenue arises when batches and associated services are delivered, not when the full contract is signed. Sponsors still face risks from forecast changes and manufacturing slots reserved ahead of demand.

GMP quality obligations favor established contract manufacturers

The FDA’s November 2016 guidance on quality agreements describes how drug owners and contractors document responsibilities for production, testing, deviations and release. EMA requirements extend GMP supervision to manufacturing sites outside the European Union when they supply EU medicines. Experienced CDMOs can provide validated procedures, inspection histories and trained quality personnel that new facilities must build from the ground up. Sponsors remain responsible for their licensed products, making technical oversight necessary even after outsourcing. Quality failures or incomplete transfer records can delay clinical supply and interrupt commercial production.

Complex antibodies and conjugates require specialized production steps

Boehringer Ingelheim and Sutro announced in July 2025 that a cell-free process for an investigational antibody-drug conjugate had been scaled to 4,500-liter GMP batches in Vienna. Abzena established a scientific advisory board in May 2025 focused partly on complex biologics and bioconjugates. These technologies require specialized purification, analytical characterization and process controls beyond conventional antibody culture. A manufacturer capable of linking development with GMP execution can reduce the number of sponsor transfers. Nevertheless, each technology needs product-specific qualification before clinical or commercial use.

Capital intensity and utilization restrain supplier profitability

Lonza reported CHF 1.3 billion of capital expenditure in 2025, equivalent to 19.6% of continuing sales, while integrating its Vacaville manufacturing operation. Large facilities carry fixed costs for utilities, maintenance, quality systems and specialist staff even when customers delay campaigns. Biologics batches also require extensive comparability evidence when processes or sites change, limiting quick substitution of unused capacity. Contractors therefore balance multi-year reservations against the risk of idle equipment. Competitive pricing for standard production services can weaken returns unless utilization and execution remain strong.

Regional resilience influences contract awards and plant investment

Thermo Fisher acquired Sanofi’s Ridgefield sterile manufacturing site in September 2025 and continued producing therapies for Sanofi while offering capacity to other customers. In February 2025 the European Critical Medicines Alliance recommended investment and diversification to reduce medicine supply vulnerabilities. Sponsors increasingly consider regional redundancy, inspection readiness and transfer time when selecting production partners. A second qualified site may be justified even if a single factory has lower unit costs. Geographic resilience becomes especially valuable for products with limited alternate supply or sensitive cold-chain requirements.

Sources: FDA quality agreements and Q5E; EMA GMP; Lonza FY2025; FUJIFILM Biotechnologies; Thermo Fisher; European Commission.

Large mammalian production campuses support multiyear supply commitments

The Holly Springs facility opened by FUJIFILM Biotechnologies in 2025 contains eight 20,000-liter mammalian trains, with a second phase planned to add another eight. Samsung Biologics reported that its first four plants had achieved full utilization during 2025. These examples show how commercial antibodies depend on both installed equipment and sustained customer programs. Capacity announcements do not create revenue until a validated process operates and invoices are earned. New campuses must secure enough contracted work to absorb depreciation, utilities and the cost of maintaining GMP staff.

Integrated providers are adding conjugation and analytical capabilities

Abzena announced a scientific advisory board in May 2025 addressing antibody-drug conjugates, antibody-oligonucleotide conjugates and bispecific molecules. Boehringer Ingelheim demonstrated a specialized cell-free production transfer with Sutro in July of that year. Such work requires coordination between biologic drug substance, conjugation chemistry and product-release analytics. Sponsors may value a single provider that can manage several linked stages without repeated handoffs. The commercial opportunity lies in documented services supplied to independent customers, rather than counting research milestones or the eventual therapeutic product value.

Sterile manufacturing acquisitions create alternative qualified locations

Thermo Fisher’s September 2025 acquisition of the Ridgefield facility preserved Sanofi supply while adding U.S. sterile fill-finish capacity for other pharmaceutical customers. Acquiring an existing operation can bring trained personnel and established systems into a contract network more quickly than building a new factory. Integration still requires careful management of batch records, quality procedures and customer agreements. The economic benefit depends on securing additional production programs without disrupting incumbent supply. The acquisition approach complements FUJIFILM’s greenfield investment in mammalian drug-substance manufacturing at Holly Springs.

Advanced-therapy technology transfer develops manufacturing capability

WHO reported fourteen manufacturing partners beyond its South African mRNA hub as of May 2025. The programme transfers process know-how, training and technical support across multiple countries. Cell, gene and RNA therapies often require smaller, more controlled batches than large-volume antibody products, increasing the importance of flexible equipment and specialist personnel. Publicly financed research and internal institutional production are not automatically commercial CDMO sales. Future outsourced revenue depends on qualified sites performing paid work for separate sponsors under defined quality agreements.

Regional industrial programmes widen potential manufacturing locations

Brazilian institution Fiocruz reported development of a domestic mRNA platform in August 2025, while the European Commission proposed its Critical Medicines Act in March 2025. Both initiatives address production capability and supply resilience, although they operate under different financing models. New skills, process documentation and local supply chains may eventually support external manufacturing contracts. Commercial revenue is realized only when an independent sponsor buys production services. Regional diversification could also reduce exposure to cross-border shipment disruption and long technology-transfer timelines.

Outsourced biomanufacturing covers distinct technical steps from upstream cultivation to sterile release. Service agreements can cover several steps, but the revenue of a single batch is recorded once at the contractor’s earned fee. GMP documentation and product-specific process comparability are necessary throughout the chain.

Upstream capacity is economically significant for marketed monoclonal antibodies that require repeat production. FUJIFILM’s ten-year Regeneron agreement illustrates how a sponsor can reserve production ahead of future demand. Contract value should be recognized over the delivery period, while manufacturing plant construction and capital equipment are outside service revenue. A large reactor network can support several molecules but must be validated for each process before batches enter the commercial supply chain.

Boehringer Ingelheim’s July 2025 announcement described a 4,500-liter GMP production campaign using Sutro’s cell-free expression technology. The process produced material meeting criteria for clinical studies; the announcement did not constitute approval of the investigational drug. Specialized analytical methods, contamination controls and process documentation can command additional fees. Such fees qualify only when an independent customer purchases them as part of the manufacturing contract.

Thermo Fisher’s Ridgefield acquisition illustrates the drug-product end of the value chain. A sterile site needs validated aseptic procedures, packaging controls, batch documentation and release testing. FDA quality-agreement guidance requires the sponsor and contractor to define how these activities are managed. EMA GMP requirements further affect products imported into the European Union, so international manufacturing networks must maintain consistent inspection readiness.

The Type dimension classifies agreements by production governance rather than technical process. Cooperative Manufacturing covers jointly managed, risk-sharing contracts; Conventional Outsourcing covers other purchased manufacturing and reserved-capacity services. Every customer agreement is assigned to one type according to its primary legal structure.

Both arrangements can support commercial antibodies, vaccines and advanced therapies. The service buyer also evaluates GMP qualification, scheduling and product-specific technical transfer before choosing the agreement. Contract duration, intellectual-property ownership and capacity commitments affect pricing, but do not change the distinction between the two governance models.

Application follows the direct customer procuring the contract service. Medical Company includes medicine developers buying clinical or commercial manufacturing; Clinical Laboratory covers laboratory purchasers; Academic Research covers university-led production; Others includes public institutions and remaining buyers. The customer named on each paid manufacturing invoice determines its mutually exclusive Application classification.

Academic Research and Others include investigator-sponsored projects, public programmes and remaining direct purchasers. These customers often commission small specialized lots requiring analytical characterization, unlike recurring commercial antibody campaigns. Grant expenditure and internal institutional work are excluded unless a separate provider earns a manufacturing fee.

End User classifies the ultimate biological product sponsor, rather than the direct contracting intermediary. Pharmaceutical Companies, Biotechnology Firms, Academic Institutions and Other Sponsors are separate groups. A laboratory buying a batch on behalf of a pharmaceutical sponsor is recorded once under the laboratory Application and the pharmaceutical End User.

Academic Institutions represent investigator-controlled projects, while Other Sponsors include government and nonprofit product programmes. End-user classification follows ultimate programme control even when the contracting laboratory is a separate organization. The WHO mRNA technology-transfer initiative supports manufacturing expertise but does not convert every publicly funded activity into commercial outsourcing revenue.

Service Level is determined by the regulatory stage of the batch or contracted production deliverable. Preclinical Development includes nonclinical process work, Clinical Phase Manufacturing includes investigational human-study material, and Commercial Production covers routine marketed-product batches. A single invoice is assigned to the stage of the work delivered.

Preclinical Development includes early external process optimization and nonclinical batch work. Manufacturers distinguish these preclinical deliverables from human-study GMP batches by their intended regulatory use and contractual documentation. Its smaller campaigns provide a potential path toward later manufacturing contracts, but discovery-only research without a production deliverable is excluded.

Regional demand reflects the location of qualified production assets, sponsor contracts and inspection regimes. The five-region allocation assigns revenue to the location where the contracted service is performed, rather than the sponsor headquarters, preventing cross-border duplication.

Manufacturing procurement requires the sponsor and contractor to document technical responsibilities, quality oversight, intellectual-property access and release procedures. Long-term reservations can support new facilities, but suppliers earn revenue only as agreed manufacturing work is delivered.

FDA guidance describes how owners and contractors can allocate manufacturing tasks in a written quality agreement. The contractor must operate in accordance with applicable CGMP, while the product owner retains its regulatory responsibilities. Agreements commonly cover deviations, batch records, analytical testing, release decisions and change notification. Clear duties reduce the chance that a technical issue remains unresolved between organizations, but a contract cannot eliminate either party’s statutory obligations.

FUJIFILM’s April 2025 agreement with Regeneron extends over ten years and has an announced value above USD 3 billion. The duration provides a basis for capacity planning and plant investment, yet the full agreement value is not a single-period market sale. Contractors still face execution risk if a sponsor changes forecasts, encounters clinical delays or requests a process modification that requires additional qualification.

EMA GMP rules apply to imported medicinal products, and EudraGMDP records relevant manufacturing authorizations and certificates. Sponsors purchasing production across borders must consider inspection readiness, transport validation and the ability to maintain product specifications after transfer. FDA Q5E guidance similarly addresses comparability after biological manufacturing changes. These requirements create demand for technical-transfer services but also raise the time and cost needed to establish a second source.

Source: FDA quality agreements; EMA GMP; FUJIFILM–Regeneron.

Contract biological production remains subject to the quality requirements governing the medicinal product. Regulators evaluate the manufacturing process, testing and documentation, not merely the presence of equipment or a general facility certificate.

FDA Q5E guidance addresses evidence needed to demonstrate that manufacturing changes do not adversely affect a biological product’s quality, safety or efficacy. The assessment can involve analytical characterization, functional testing and additional studies depending on the nature of the change. Consequently, a new reactor or manufacturing location cannot automatically replace an approved process without product-specific work. Contractors with experienced comparability teams can support sponsors through technical transfer and regulatory submissions.

European authorities inspect manufacturing facilities supplying medicines to the European Union, including overseas sites where relevant. The EMA describes the roles of national competent authorities and the EudraGMDP database in recording manufacturing authorizations, GMP certificates and noncompliance statements. These systems provide important due-diligence information, but a general GMP certificate does not substitute for validating a specific biological product process. International CDMOs must maintain inspection-ready documentation across multiple sites.

WHO’s mRNA technology-transfer programme had fourteen manufacturing partners beyond its South African hub by May 2025. Its purpose includes transferring production knowledge and building sustainable regional capability. Such programmes may expand the pool of technically capable suppliers, but they do not themselves quantify commercial outsourced revenue. Paid third-party manufacturing requires distinct sponsor agreements, qualifying production activities and records that meet the regulatory requirements of the intended market.

Contract biomanufacturing competition includes global mammalian cell-culture operators, sterile drug-product specialists and providers of complex conjugate and advanced-therapy processes. The ability to deliver qualified batches, sustain utilization and complete transfers matters more than nameplate bioreactor capacity alone.

Company portfolios must be distinguished from the narrower market boundary. Lonza includes small-molecule and specialized services; Thermo Fisher has a large laboratory and analytical business; and WuXi Biologics combines research, development and manufacturing activities. Counting consolidated group sales as biological production fees would overstate the market. Catalent is owned by Novo Holdings following its 2024 acquisition and should not be presented as an independent publicly traded company. FUJIFILM Diosynth Biotechnologies operates under the FUJIFILM Biotechnologies name.

Competitive positioning depends on a manufacturer’s ability to keep validated production capacity occupied without sacrificing quality. Samsung’s full-utilization update and Lonza’s Vacaville integration show how established facilities can attract recurring work. Smaller suppliers may differentiate through bioconjugation, specialized analytical methods, clinical-batch flexibility or geographic proximity. Buyers also consider data controls, technology-transfer timelines, regulatory history and the financial stability of a provider before signing multiyear commitments.

• Lonza Group AG
• Samsung Biologics Co., Ltd.
• FUJIFILM Biotechnologies
• WuXi Biologics
• Thermo Fisher Scientific Inc.
• Boehringer Ingelheim BioXcellence
• Abzena plc
• Syngene International Limited
• Catalent, Inc.
• Charles River Laboratories
• Recipharm AB
• AGC Biologics

Global revenue is forecast to rise from USD 20.3 billion in 2026 to USD 46.7 billion by 2034, equivalent to an 11.0% CAGR. The outlook depends on qualified capacity, complex biological pipelines and the conversion of long-term manufacturing commitments into delivered services.

Large mammalian facilities should increase available contract supply, but additional revenue requires qualified customer programmes and reliable utilization. FUJIFILM’s phased Holly Springs development and Samsung Biologics’ existing plant network illustrate different positions in the capacity cycle. New facilities must complete equipment qualification, process transfer and product-specific regulatory work before routine commercial batches can be released. Construction announcements therefore cannot be equated with immediate manufacturing sales.

Complex antibodies, conjugates and advanced therapies increase demand for process development, analytical release and specialist manufacturing. Boehringer’s cell-free expression collaboration and Abzena’s complex-biologics focus illustrate the technical range of services available to sponsors. Integrated providers can reduce handoffs between production steps, although process changes still require comparability evidence. The value recognized within the market remains the earned fee for qualifying work, not a sponsor’s eventual drug sales.

North America should retain the largest revenue base through the forecast because of major sponsor demand and substantial validated manufacturing infrastructure. Europe offers established GMP expertise, while Asia-Pacific provides expanding commercial bioreactor networks. Latin America and Africa may develop selectively through vaccine technology transfer and local production initiatives. Public grants and internal institutional programmes do not enter the commercial total unless they result in paid services supplied to independent customers.

Risks include underutilized new plants, delayed clinical programmes, regulatory findings, batch failures, technology-transfer problems and price pressure in standardized services. Multiyear contracts can support investment decisions but may also concentrate supplier revenue on a limited number of sponsors. Providers combining reliable GMP execution, geographic flexibility and specialist process capabilities are positioned to maintain stronger utilization as biological pipelines and sourcing strategies change.

Coverage examines third-party biological production services, contract structures, sponsor categories, regulatory requirements, manufacturing capacity and five global regions.